Gilead's Q2 Said 10% Growth-But an $8.45 Loss Forces Investors to Look Deeper

The main tension: strong top-line growth versus a heavy acquisition-driven earnings hit

August 4 changed the setup. Gilead released its second quarter 2026 financial results after the close and hosted a webcast at 4:30 p.m. Eastern Time the same day, leaving investors little time to absorb the numbers before evaluating the story. The key question became whether this was still a normal operating quarter with a temporary accounting hit-or an early sign that acquisition-related charges could materially change how the company is valued.

The positive side was straightforward. Total second quarter 2026 revenues increased 10% to $7.8 billion, product sales excluding Veklury rose 10% to $7.6 billion, and Biktarvy sales increased 7% to $3.8 billion. In other words, the core revenue engine was still growing. That is why the debate around the stock remains alive.

The negative side explains why the quarter still had to change the conversation. Diluted loss per share was $(8.45), and non-GAAP diluted loss per share was $(6.75), both reflecting a $(9.08) per share impact from acquired IPR&D and related tax expenses tied to recent deals. Bulls can treat that as a timing-related acquisition charge. Bears can argue it shows how expensive Gilead's growth strategy is becoming when booked through earnings. The split now is simple: view it as a one-quarter valuation scare, or start pricing the business as if those costs are an upfront payment for future growth.

Core operating trends still look healthy

The operating figures suggest Gilead's underlying business is still intact.

Base-business growth improved from Q1 to Q2

In the first quarter, management reported 8% year-over-year growth in base business. By the second quarter, that broadened to 10% year-over-year revenue growth in our base business. Management also said HIV sales grew 12% in Q2. That kind of acceleration is encouraging for a mature biopharma company and suggests the growth was not limited to a single product.

HIV remains the franchise anchor

That core franchise is still building momentum. Gilead entered 2026 after the successful U.S. launch of Yeztugo, and management tied the stronger second-quarter HIV results to ongoing treatment strength and expanding PrEP adoption. That matters because HIV has long been one of Gilead's strongest commercial areas, and continued growth there helps support the case for durable cash generation.

Trodelvy and Livdelzi are helping diversify the mix

Management also said second-quarter base growth was driven by the HIV portfolio, Trodelvy, and Livdelzi. That makes the quarter more credible than a Biktarvy-only story. At the same time, Gilead still faced headwinds elsewhere, including weaker Cell Therapy and chronic HCV product sales, which is a reminder that the transition is still uneven.

What decides the next leg of the story

The core business still looks strong enough to support a constructive view. What changes now is the time frame. Over the next few quarters, investors need to see whether recent acquisitions are laying the groundwork for real commercial scale-or simply adding more future promise on top of a large earnings charge.

Why the bull case still holds up

The bull case is not abstract. Gilead has long-acting HIV therapies in the pipeline, which matters because improved dosing can be more than a scientific milestone; it can translate into a competitive commercial tool in a franchise investors already understand. Management has also pointed to potential new launches across cancer and HIV, while emphasizing that recent acquisitions are meant to add assets in oncology and inflammation. If those assets move from promise to revenue, the earlier acquisition costs will look more like pipeline acceleration and more like commercial expansion.

Why the bear case still matters

The bear case is simpler: acquisition-led growth can remain expensive for longer than investors expect. If Gilead continues to absorb heavy acquired IPR&D-style charges before those deals produce matching revenue, investors will effectively be funding the transition before the payoff is visible.

What to watch over the next few quarters

• Biktarvy: maintain its lead.
• Livdelzi: build on the strong early contribution.
• Yeztugo: turn early traction into sustained PrEP growth.
• Oncology and inflammation: show measurable commercial progress rather than just pipeline promise.

If that conversion stalls, or if acquisition costs keep outrunning commercial scale, the re-rating case weakens. The same is true if HIV growth cools after a quarter supported by our HIV portfolio.

The main takeaway is simple: separate the operating trend from the accounting hit. Even after this quarter, Gilead still looks more like a longer compounding story than a fully resolved one.